CRT Licenses Antibody Technology to Glycart
London UK; 17th January 2008 - Cancer Research Technology Limited (CRT), the specialist oncology-focused development and commercialisation company, today announced it has granted an exclusive worldwide licence to Glycart Biotechnology, a member of the Roche group, to develop a preclinical antibody for the treatment of cancer.
The licensed antibody selectively binds to a cell surface-presented protein that is over-expressed in certain types of cancer including colorectal cancer. The antibody was originally developed by Cancer Research UK.
Glycart will use its proprietary GlycoMAB technology to enhance the in vivo efficacy of the antibody. A research collaboration between CRT, Glycart and the University of Oxford has been established to investigate the potential efficacy of the glyco-engineered antibody in pre-clinical studies
Dr Phil L’Huillier, CRT’s director of business management, said: “This is a significant step forward in the development of this technology as a therapeutic agent. We’re very pleased that Glycart is taking this exciting antibody forward and we look forward to the development of a therapeutic that will help treat bowel cancer more efficiently.”
ENDS
For media enquiries please contact Sophy Fitzpatrick in the Cancer Research Technology Ltd press office on 020 7061 8318 or, out of hours, the duty press officer on 07050 264059.
Notes to editors:
Cancer Research Technology
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found at www.cancertechnology.com
Cancer Research UK
Together with its partners and supporters, Cancer Research UK's vision is to beat cancer. The charity carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer. It ensures that its findings are used to improve the lives of all cancer patients. Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make. The charity works in partnership with others to achieve the greatest impact in the global fight against cancer. For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 7009 8820 or visit www.cancerresearchuk.org
University of Oxford
The University of Oxford is ranked third in the world for biomedicine (Times Higher Education Supplement). Oxford’s Medical Sciences Division is one of the largest biomedical research centres in Europe and accounts for a third of the University’s income and expenditure and two thirds of external research income. A strong research programme in cancer is supported by a new Institute for Cancer Medicine, to open in 2008, opposite the city's new £100m cancer hospital. www.ox.ac.uk
|
